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flat	 topped	papules	or	brown-grey	macules,	which	are	 intensely	 itchy	
1
.	Underpinning	 the	
clinical	 manifestations	 is	 the	 deposition	 of	 beta-sheets	 of	 extracellular	 protein	 in	 the	
papillary	 dermis,	 thought	 to	 arise	 from	 degenerate	 protein	 from	 basal	 keratinocytes,	














OSM	 type	 2	 receptor,	 it	 can	 induce	 apoptosis
	 5
.	 The	 exact	 function	 and	 downstream	
signalling	of	OSMR-β,	as	well	as	its	role	in	PLCA,	has	yet	to	be	fully	identified	but	a	reduction	
in	 OSMR-β	 signalling	 could	 explain	 the	 increased	 apoptosis	 of	 basal	 cell	 keratinocytes	
associated	with	PLCA.		
	
A	 35	 year	 old	 Caucasian	 male	 presented	 with	 pruritic	 papules	 on	 his	 lower	 leg	 since	
adolescence	 (Fig.	 1a).	 A	 skin	 biopsy	 of	 a	 lesion,	 from	 the	 patient	 and	 his	 mother,	 both	
demonstrated	extracellular	protein	deposits	were	 seen	 in	 the	papillary	dermis,	which	was	
congo	red	and	thioflavin	T	positive	(Fig.	1b,c).	Written	informed	consent	was	obtained	from	





indicate	 that	 amino	 acids	 p.R438	 is	 	 conserved	 across	 several	 species	 (Fig.	 1e),	 the	
incorporation	 of	 a	 basic	 lysine	 into	 the	 fibronectin	 III	 (FNIII)	 repeat	 of	 the	 extracellular	
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Figure	Legends	
	
Figure	1.	(a)	Numerous	firm	skin	coloured	papules	on	the	lower	limbs.	Skin	histology	
demonstrated	a	mild	acanthosis,	with	dermal	deposit	which	was	congo	red	positive	(b)	and	
demonstrated	thioflavin	T	stain	fluorescence	(c).	(d)	Electropherogram	of	sequencing	by	
forward	(and	reverse)	primers	identified	a	heterozygous	mutation	c.1715G>A	in	affected	
family	members,	leading	to	a	change	in	amino	acid	p.R438K	at	a	conserved	site	(e),	
representing	a	novel	mutational	site	in	the	predicted	protein	(f).			
	
	
	
